Abstract
Viral respiratory infections (VRI) are the most prevalent type of infectious diseases and constitute one of the most common causes of contact with medical care. Regarding the pathophysiology of the cardiovascular system, VRI can not only exacerbate already existing chronic cardiovascular disease (such as coronary artery disease or heart failure) but also trigger new adverse events or complications (e.g., venous thromboembolism), the latter particularly in subjects with multimorbidity or disease-related immobilization. In the current paper, we provide a narrative review of diverse cardiovascular complications of VRI as well as summarize available data on the pathology of the circulatory system in the course of coronavirus disease 2019 (COVID-19).
1. Introduction
Viral respiratory infections (VRI) are among the most common reasons of contact with health care in both adults and children [1]. From a global perspective, respiratory infections are the most prevalent type of infectious diseases and one of the leading causes of death, following only ischemic heart disease, chronic obstructive pulmonary disease, and stroke, and are responsible for 120 million disability-adjusted life years worldwide [2,3,4]. Viral etiology remains the most common in both respiratory infections in total and also in the subgroup of subjects with pneumonia—the most severe type of infectious involvement of the respiratory tract [5,6].
The most frequently identified viruses in patients with acute presentations of VRI are influenza virus, rhinoviruses, respiratory syncytial virus (RSV), parainfluenza virus, human metapneumovirus, respiratory adenoviruses, and coronaviruses [1,7,8,9]. However, it needs to be acknowledged that multiple viral pathogens are found in many subjects [10]. Respiratory viruses are transmitted predominantly via inhalation of infectious droplets or contact with contaminated secretions [1]. Clinical manifestations of VRI are heterogeneous and may involve the upper and/or lower respiratory tract, comprising rhinosinusitis, pharyngitis, the common cold, laryngotracheitis, bronchitis, bronchiolitis, and eventually overt pneumonia [11]. From the point of view of the cardiovascular system, VRI may not only exacerbate already existing chronic cardiovascular disease (such as coronary artery disease or heart failure) but also trigger new adverse cardiovascular events/conditions, the latter particularly in subjects with multimorbidity or immune deficits (Figure 1). Currently, due to the latest research boosted by the coronavirus disease 2019 (COVID-19) pandemic, our knowledge of and interest in the pathophysiology of VRI have considerably increased. In the current paper we provide a narrative review on diverse cardiovascular complications of VRI, as well as a summary of available data on the involvement of the cardiovascular system in the course of COVID-19.
Figure 1.
In predisposed patients, common upper and lower respiratory tract infections of viral etiology may be complicated by adverse cardiovascular events and conditions, the pathophysiology of which is diverse and not always thoroughly investigated. The pathomechanisms of myocardial ischemia and pulmonary embolism are presented in Figure 2. Abbreviations: CV—cardiovascular, DNA—deoxyribonucleic acid, RNA—ribonucleic acid, RSV—respiratory syncytial virus.
2. Ischemic Complications
From a pathophysiological point of view, myocardial ‘ischemia’ results from an imbalance between myocardial oxygen demand/supply, whereas myocardial ‘injury’ is defined as any damage to myocardial cells that is accompanied by the release of cardiac necrotic biomarkers [12]. It needs to be acknowledged that the prevalence of myocardial infarction (MI) varies seasonally and is highest in the winter [13]. The number of daily hospitalizations rises starting in August and reaches its peak in January [13]. This seasonality is not fully explained, but the increased incidence of upper respiratory tract infections is considered to play a role due to their multifaceted impact on blood rheology and therefore the functioning of the cardiovascular system [13]. The total risk for cardiovascular complications is determined primarily by the severity of the respiratory infection [14,15]. Although cardiac troponins above the upper limit of normal are frequently detected in the peripheral blood of patients with ongoing severe VRI [16,17], the most frequent pathomechanism is presumably the direct/indirect influence of the viruses themselves on cardiomyocytes (myocardial injury) [14].
The risk of MI during the first week following VRI is significantly increased (up to 6-fold) and remains elevated during one month of observation in Scottish records of the 10-year national infections registry, including 1989 individuals with acute ischemic cardiovascular events [18]. Similar trends have also been demonstrated for incident stroke, and therefore it should be assumed that the increased risk should be attributed to the entire spectrum of atherosclerotic cardiovascular disease (ASCVD). It is worth noting that the risk of an acute cardiovascular event was also related to previous ASCVD burden (the highest in patients with a history of previous MI) and the type of infection (the highest in influenza) [19,20]. There is evidence from longitudinal observations for an increased risk for ASCVD-related morbidity and mortality (including MI, stroke, or cardiovascular death) for a 10-year period following the hospitalization for any severe or non-severe pneumonia [21].
There are several pathophysiological links between VRI and the triggering or worsening of myocardial ischemia, including (i) inflammation; (ii) prothrombotic imbalance; (iii) hypercoagulability; and (iv) increased metabolic demands of the myocardium [22,23,24] (Figure 2). The process of inflammation not only activates platelets but also stimulates inflammatory cells within atherosclerotic plaques. The latter results in the release of metalloproteinases and peptidases, which can contribute to plaque destabilization [23,24]. Moreover, circulating pro-inflammatory cytokines can negatively impact the process of atherosclerotic remodeling of the vessel wall through modulating monocyte adhesion, macrophage activation, and proliferation of smooth muscle cells [24]. In parallel, up-regulated synthesis of thromboxane and tissue factor expression on immune cells, as well as the impairment of fibrinolysis and anticoagulant function of the endothelium, lead to increased thrombogenicity and a hypercoagulability state [24]. The anticoagulant dysfunction is associated with the downregulation of protein C, while the disturbance of fibrinolysis is associated with an increase in plasminogen activator inhibitor 1 [24].
Figure 2.
Multifaceted and overlapping mechanisms of arterial ischemic and venous thromboembolic complications of viral respiratory infections.
3. Thromboembolism
Infections per se augment the risk of venous thromboembolism (VTE) up to about two times in records from over 10,000 individuals with urinary or respiratory tract infections [25]. Respiratory infections are associated with increased risk of both components of VTE, analyzed separately: deep vein thrombosis (DVT) and pulmonary embolism (PE) [25]. The overlapping of symptoms between PE and respiratory infection makes it frequently difficult to establish the chronology of these clinical entities in clinical practice [25].
The established pathomechanisms linking infection and thromboembolism include not only platelet activation and up-regulated synthesis of pro-coagulant proteins but also the impairment of fibrinolysis and anticoagulant function of the endothelium [26] (Figure 2). Moreover, the activation of leukocytes, triggered by infection, is associated with the release of damage-associated molecular patterns (such as deoxyribonucleic acid or histones), which further promotes thrombus formation [26]. It also needs to be acknowledged that local inflammatory reactions, for example in the lungs, result in the disruption of endothelial cell membranes, which is followed by vascular thrombosis, microangiopathy, and increased angiogenesis [27,28]. Venous stasis, which is prevalent in immobile critically ill patients undergoing mechanical ventilation and presenting with microvascular pulmonary injury, is another pathomechanism increasing thromboembolic events in such patients [29].
4. Viral Myocarditis and (Post-)Inflammatory Cardiomyopathy
Despite many new experimental studies, our understanding of the development, evolution/progression, and recovery (or not) from an acute/sub-acute myocarditis is still not sufficient, and several pathways/mechanisms are constantly being explored, including the role of immune cells (also autoimmunity), the pathobiology of particular viruses, and iron metabolism, to name but a few [30,31,32,33]. Respiratory viruses are established to be the most common triggers of myocarditis, and the most frequently identified/isolated ones are adenoviruses, enteroviruses, influenza virus, and coronaviruses [30,34,35]. The incidence of particular viral infections fluctuates seasonally, with the peak of influenza in the winter and enteroviruses in the summer and autumn [30]. Clinical presentation of viral myocarditis is heterogeneous and comprises a broad spectrum of symptoms, from chest pain (ischemic-like or pleuritic-like), dyspnea, and fatigue, through less specific palpitations or syncope, to fulminant life-threatening conditions such as cardiogenic shock, ventricular arrhythmias, or even sudden cardiac death [36].
Adenoviruses and enteroviruses are positioned among the most common etiological factors of myocarditis [34]. They represent a group of primary cardiotropic viruses, responsible for direct damage to myocardial tissue. Viral invasion into cardiomyocytes occurs via the transmembrane receptor and is followed by viral replication inside, leading to the destruction of the cytoskeleton, cytolysis, and eventually an immune cell reaction [30,37,38]. Persistent viral activity following the acute phase of the disease can result in progressive cardiac dysfunction with a poor prognosis [35]. There is evidence that, for example, in enteroviral myocarditis, the recovery from an acute condition defined as complete virus clearance occurs in only half of subjects [39]. In this context, it is worth noting that entero- or adenoviral genomes were detected in 26% of patients with idiopathic left ventricular dysfunction and in 13% of patients with idiopathic dilated cardiomyopathy. However, it should be stipulated that this does not prove causality [35,40].
Influenza A and influenza B viruses (together with the Coronaviridae family described below) are classified as cardiotoxic agents, provoking myocarditis indirectly; these viruses activate the immune system responses, leading to augmented cytokine release and cytokine-mediated myocardial damage [30,41]. Influenza myocarditis is considered infrequent but associated with a poor outcome, with a mortality rate ranging up to 30% in H1N1 subtype infections [41].
5. Pericardial Disease
In developed countries, viral etiology is the most common in both acute pericarditis and pericardial disease as a whole [42,43]. Acute pericarditis is an inflammatory disease characterized by infiltrates of immune cells into the pericardium triggered mainly by viruses and resulting in a clinical syndrome characterized by typical signs and symptoms (pericarditic type of chest pain, specific electrocardiogram (ECG) abnormalities, and pericardial effusion) [42,44]. The common course of the disease is benign with mild to moderate symptoms that can be successfully treated outpatiently with non-steroidal anti-inflammatory agents and colchicine. More severe complications, including cardiac tamponade with a worse prognosis, are rather rare [44,45]. 33% of patients with acute pericarditis have a history of a recent upper respiratory tract infection [46]. Among respiratory viruses, enteroviruses, adenoviruses and influenza virus are the most prevalent in patients with pericarditis, being identified in 25%, 19%, and 6% of patients, respectively [47]. Differences in the clinical course of the disease according to particular groups of viruses have not been investigated. Not infrequently, pericarditis is accompanied by the involvement of myocardial muscle, which results in a syndrome of ‘myopericarditis’ [47,48]. This condition is associated with enteroviral infection in 15% and adenoviral, influenza, or parainfluenza in 10% each [47,48].
6. Pro-Arrhythmia
Diverse cardiovascular and non-cardiovascular factors (the latter including, for example, dehydration and electrolyte disturbances caused by hyperthermia or diarrhea) contribute to pro-arrhythmia in the course of VRI. Not surprisingly, the patients most vulnerable to severe arrhythmic complications are those who already have a chronic cardiovascular disease (such as heart failure or non-revascularized coronary artery disease) that may be a substrate for life-threatening ventricular arrhythmias [30,49,50]. Obviously, both supraventricular and ventricular arrhythmias can also be triggered by direct (e.g., cardiomyocyte invasion in acute myocarditis complicating VRI) or indirect (e.g., in the course of excessive pro-inflammatory cytokine release) myocardial injury associated with an infection that is initially limited to the respiratory system [30]. Regarding the impact of severe respiratory infection on the functioning of the cardiovascular system, it also needs to be acknowledged that coexistent (sub-)acute myocardial ischemia (resulting from, e.g., hypoxemia, hypoperfusion, or tachycardia, to name but a few) can also promote arrhythmic episodes [22,23,24].
Epidemiological data show interesting trends: seasons with higher influenza activity are characterized by an increased risk of device-detected ventricular arrhythmias treated with appropriate therapies in patients with implantable cardioverter-defibrillators [51]. In one analysis of a large cohort of patients, it has been demonstrated that the prevalence of ventricular arrhythmia requiring high-energy discharge or antitachycardia pacing therapy followed the community activity of the influenza virus [51]. This relationship can be potentially explained by inflammation, exacerbation of heart failure or coronary artery disease, and increased myocardial oxygen demand [51]. Furthermore, among adult patients hospitalized due to RSV infection, 8% developed a new arrhythmia, and after considering all cardiovascular complications, only exacerbation of heart failure symptoms was slightly more frequent in this group of subjects [52].
Life-threatening ventricular arrhythmias or severe cardiac conductance disorders are most likely to occur in the course of giant-cell myocarditis [30,49,53]. The pathomechanism of significant (ventricular) arrhythmias in patients with (sub-)acute myocarditis is complex and there is evidence on the contribution of direct viral invasion within cardiomyocytes, microvascular ischemia, proarrhythmic properties of particular cytokines, abnormal calcium handling, and deranged ion channel functioning [54,55]. Pericarditis can also be complicated by arrhythmias, although it is considerably less prevalent than myocarditis [48].
8. Conclusions
Some cardiovascular complications of VRI are well characterized; for example, we know in detail how such infections adversely affect blood rheology or endothelial function. In the course of, for example, COVID-19, pathophysiological aspects such as hypoxemia due to severe respiratory failure or a cytokine storm have also been intensively studied in the context of the impact on the circulatory system. On the other hand, we still do not know much about what happens at the virus-cardiomyocyte level, i.e., which factors determine, for example, the development of acute/sub-acute myocarditis (complicating a common viral upper respiratory tract infection) or the conversion of acute inflammatory myocardial involvement to chronic post-inflammatory cardiomyopathy. A more precise understanding of these pathomechanisms will not only allow us to identify more precisely subjects at risk of the most severe VRI cardiovascular complications (cardiomyopathy with severe symptoms of heart failure), but it may also allow us to develop effective causal or even prophylactic anti-inflammatory/immunosuppressive therapies, which in a carefully selected group of patients may reduce morbidity and mortality.
Author Contributions
Conceptualization, P.F., M.T. and E.A.J.; review of literature, P.F., M.T., M.K. and E.D.; writing—original draft preparation, P.F., M.T., M.K. and E.D.; writing—revisions, P.F., M.T.; critical revision of the manuscript for important intellectual content, M.T., P.P. and E.A.J. All authors have read and agreed to the published version of the manuscript.
Funding
This research was financially supported by subsidy no. SUBZ.A460.22.055 of the Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Acknowledgments
Not applicable.
Conflicts of Interest
P.F., M.T., M.K., E.D. and P.P. declare no conflicts of interest. E.J. reports grants and personal fees from Vifor Pharma and personal fees from Bayer, Novartis, Abbott, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, Berlin Chemie, Cardiac Dimensions, Takeda, Gedeon Richter, and Respicardia outside the submitted work.
References
- Charlton, C.L.; Babady, E.; Ginocchio, C.C.; Hatchette, T.F.; Jerris, R.C.; Li, Y.; Loeffelholz, M.; McCarter, Y.S.; Miller, M.B.; Novak-Weekley, S.; et al. Practical Guidance for Clinical Microbiology Laboratories: Viruses Causing Acute Respiratory Tract Infections. Clin. Microbiol. Rev. 2018, 32, e00042-18. [Google Scholar] [CrossRef] [Scilit]
- Varghese, B.M.; Dent, E.; Chilver, M.; Cameron, S.; Stocks, N.P. Epidemiology of viral respiratory infections in Australian working-age adults (20–64 years): 2010–2013. Epidemiol. Infect. 2018, 146, 619–626. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tang, J.W.; Lam, T.T.; Zaraket, H.; Lipkin, W.I.; Drews, S.J.; Hatchette, T.F.; Heraud, J.M.; Koopmans, M.P.; INSPIRE Investigators. Global epidemiology of non-influenza RNA respiratory viruses: Data gaps and a growing need for surveillance. Lancet Infect. Dis. 2017, 17, e320–e326. [Google Scholar] [CrossRef] [Scilit]
- GBD 2013 DALYs and HALE Collaborators; Murray, C.J.; Barber, R.M.; Foreman, K.J.; Abbasoglu Ozgoren, A.; Abd-Allah, F.; Abera, S.F.; Aboyans, V.; Abraham, J.P.; Abubakar, I.; et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: Quantifying the epidemiological transition. Lancet 2015, 386, 2145–2191. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Walter, J.; Wunderink, R. Severe Respiratory Viral Infections. Infect. Dis. Clin. N. Am. 2017, 31, 455–474. [Google Scholar] [CrossRef] [Scilit]
- Jain, S.; Self, W.H.; Wunderink, R.G.; Fakhran, S.; Balk, R.; Bramley, A.M.; Reed, C.; Grijalva, C.G.; Anderson, E.J.; Courtney, D.M.; et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N. Engl. J. Med. 2015, 373, 415–427. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Góes, L.G.; Zerbinati, R.M.; Tateno, A.F.; de Souza, A.V.; Ebach, F.; Corman, V.M.; Moreira-Filho, C.A.; Durigon, E.L.; da Silva Filho, L.V.; Drexler, J.F. Typical epidemiology of respiratory virus infections in a Brazilian slum. J. Med. Virol. 2020, 92, 1316–1321. [Google Scholar] [CrossRef] [Scilit]
- Eiros, J.M.; Ortiz de Lejarazu, R.; Tenorio, A.; Casas, I.; Pozo, F.; Ruiz, G.; Pérez-Breña, P. Microbiological diagnosis of viral respiratory infections. Enferm. Infecc. Microbiol. Clin. 2009, 27, 168–177. [Google Scholar] [CrossRef] [Scilit]
- Naz, R.; Gul, A.; Javed, U.; Urooj, A.; Amin, S.; Fatima, Z. Etiology of acute viral respiratory infections common in Pakistan: A review. Rev. Med. Virol. 2019, 29, e2024. [Google Scholar] [CrossRef] [Scilit]
- Ambrosioni, J.; Bridevaux, P.O.; Wagner, G.; Mamin, A.; Kaiser, L. Epidemiology of viral respiratory infections in a tertiary care centre in the era of molecular diagnosis, Geneva, Switzerland, 2011–2012. Clin. Microbiol. Infect. 2014, 20, O578–O584. [Google Scholar] [CrossRef] [Scilit]
- Subbarao, K.; Mahanty, S. Respiratory Virus Infections: Understanding COVID-19. Immunity 2020, 52, 905–909. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D. Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018, 138, e618–e651. [Google Scholar] [CrossRef] [PubMed]
- Patel, N.J.; Pant, S.; Deshmukh, A.J.; Nalluri, N.; Badheka, A.O.; Shah, N.; Chothani, A.; Savani, G.T.; Schwartz, C.; Duvvuri, S.; et al. Seasonal variation of acute myocardial infarction related hospitalizations in the United States: Perspective over the last decade. Int. J. Cardiol. 2014, 172, e441–e442. [Google Scholar] [CrossRef] [Scilit]
- Davidson, J.; Warren-Gash, C. Cardiovascular complications of acute respiratory infections: Current research and future directions. Expert Rev. Anti-Infect. Ther. 2019, 17, 939–942. [Google Scholar] [CrossRef] [Scilit]
- Madjid, M.; Safavi-Naeini, P.; Solomon, S.D.; Vardeny, O. Potential effects of coronaviruses on the cardiovascular system. JAMA Cardiol. 2020, 5, 831–840. [Google Scholar] [CrossRef] [Scilit]
- Lippi, G.; Sanchis-Gomar, F. Cardiac troponin elevation in patients with influenza virus infections. Biomed. J. 2021, 44, 183–189. [Google Scholar] [CrossRef] [Scilit]
- Guo, T.; Fan, Y.; Chen, M.; Wu, X.; Zhang, L.; He, T.; Wang, H.; Wan, J.; Wang, X.; Lu, Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020, 5, 811–818. [Google Scholar] [CrossRef] [Scilit]
- Warren-Gash, C.; Blackburn, R.; Whitaker, H.; McMenamin, J.; Hayward, A.C. Laboratory-Confirmed Respiratory Infections as Triggers for Acute Myocardial Infarction and Stroke: A Self-Controlled Case Series Analysis of National Linked Datasets from Scotland. Eur. Respir. J. 2018, 51, 1701–1794. [Google Scholar] [CrossRef] [Scilit]
- Davidson, J.A.; Banerjee, A.; Smeeth, L.; McDonald, H.I.; Grint, D.; Herrett, E.; Forbes, H.; Pebody, R.; Warren-Gash, C. Risk of acute respiratory infection and acute cardiovascular events following acute respiratory infection among adults with increased cardiovascular risk in England between 2008 and 2018: A retrospective, population-based cohort study. Lancet Digit. Health 2021, 3, e773–e783. [Google Scholar] [CrossRef] [Scilit]
- Kwong, J.C.; Schwartz, K.L.; Campitelli, M.A.; Chung, H.; Crowcroft, N.S.; Karnauchow, T.; Katz, K.; Ko, D.T.; McGeer, A.J.; McNally, D.; et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N. Engl. J. Med. 2018, 378, 345–353. [Google Scholar] [CrossRef] [Scilit]
- Corrales-Medina, V.F.; Alvarez, K.N.; Weissfeld, L.A.; Angus, D.C.; Chirinos, J.A.; Chang, C.-C.H.; Newman, A.; Loehr, L.; Folsom, A.R.; Elkind, M.S.; et al. Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease. JAMA 2015, 313, 264–274. [Google Scholar] [CrossRef] [Scilit]
- Musher, D.M.; Abers, M.S.; Corrales-Medina, V.F. Acute Infection and Myocardial Infarction. N. Engl. J. Med. 2019, 380, 171–176. [Google Scholar] [CrossRef] [Scilit]
- Corrales-Medina, V.F.; Madjid, M.; Musher, D.M. Role of acute infection in triggering acute coronary syndromes. Lancet Infect. Dis. 2010, 10, 83–92. [Google Scholar] [CrossRef] [Scilit]
- Bazaz, R.; Marriott, H.M.; Francis, S.E.; Dockrell, D.H. Mechanistic links between acute respiratory tract infections and acute coronary syndromes. J. Infect. 2013, 66, 1–17. [Google Scholar] [CrossRef] [Scilit]
- Smeeth, L.; Cook, C.; Thomas, S.; Hall, A.J.; Hubbard, R.; Vallance, P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006, 367, 1075–1079. [Google Scholar] [CrossRef] [Scilit]
- Beristain-Covarrubias, N.; Perez-Toledo, M.; Thomas, M.R.; Henderson, I.R.; Watson, S.P.; Cunningham, A.F. Understanding Infection-Induced Thrombosis: Lessons Learned From Animal Models. Front. Immunol. 2019, 10, 2569. [Google Scholar] [CrossRef] [Scilit]
- Di Minno, A.; Ambrosino, P.; Calcaterra, I.; Di Minno, M.N. COVID-19 and Venous Thromboembolism: A Meta-analysis of Literature Studies. Semin. Thromb. Hemost. 2020, 46, 763–771. [Google Scholar] [CrossRef] [Scilit]
- Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 2020, 383, 120–128. [Google Scholar] [CrossRef] [Scilit]
- Voicu, S.; Ketfi, C.; Stépanian, A.; Chousterman, B.G.; Mohamedi, N.; Siguret, V.; Mebazaa, A.; Mégarbane, B.; Bonnin, P. Pathophysiological Processes Underlying the High Prevalence of Deep Vein Thrombosis in Critically Ill COVID-19 Patients. Front. Physiol. 2021, 11, 608–788. [Google Scholar] [CrossRef] [Scilit]
- Tschöpe, C.; Ammirati, E.; Bozkurt, B.; Caforio, A.L.; Cooper, L.T.; Felix, S.B.; Hare, J.M.; Heidecker, B.; Heymans, S.; Hübner, N.; et al. Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. Nat. Rev. Cardiol. 2021, 18, 169–193. [Google Scholar] [CrossRef] [Scilit]
- Gil-Cruz, C.; Perez-Shibayama, C.; De Martin, A.; Ronchi, F.; van der Borght, K.; Niederer, R.; Onder, L.; Lütge, M.; Novkovic, M.; Nindl, V.; et al. Microbiota- derived peptide mimics drive lethal inflammatory cardiomyopathy. Science 2019, 366, 881–886. [Google Scholar] [CrossRef] [Scilit]
- Pollack, A.; Kontorovich, A.R.; Fuster, V.; Dec, G.W. Viral myocarditis-diagnosis, treatment options, and current controversies. Nat. Rev. Cardiol. 2015, 12, 670–680. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kobak, K.A.; Franczuk, P.; Schubert, J.; Dzięgała, M.; Kasztura, M.; Tkaczyszyn, M.; Drozd, M.; Kosiorek, A.; Kiczak, L.; Bania, J.; et al. Primary Human Cardiomyocytes and Cardiofibroblasts Treated with Sera from Myocarditis Patients Exhibit an Increased Iron Demand and Complex Changes in the Gene Expression. Cells 2021, 10, 818. [Google Scholar] [CrossRef] [Scilit]
- Kühl, U.; Pauschinger, M.; Bock, T.; Klingel, K.; Schwimmbeck, C.P.; Seeberg, B.; Krautwurm, L.; Poller, W.; Schultheiss, H.-P.; Kandolf, R. Parvovirus B19 Infection Mimicking Acute Myocardial Infarction. Circulation 2003, 108, 945–950. [Google Scholar] [CrossRef] [Scilit]
- Kuhl, U.; Pauschinger, M.; Noutsias, M. High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults with “Idiopathic” Left Ventricular Dysfunction. Circulation 2005, 111, 887–893. [Google Scholar] [CrossRef] [Scilit]
- Caforio, A.L.; Malipiero, G.; Marcolongo, R.; Iliceto, S. Myocarditis: A Clinical Overview. Curr. Cardiol. Rep. 2017, 19, 63. [Google Scholar] [CrossRef] [Scilit]
- He, Y.; Chipman, P.R.; Howitt, J.; Bator, C.M.; Whitt, M.A.; Baker, T.S.; Kuhn, R.J.; Anderson, C.W.; Freimuth, P.; Rossmann, M.G. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat. Struct. Biol. 2001, 8, 874–878. [Google Scholar] [CrossRef] [Scilit]
- Badorff, C.; Lee, G.-H.; Lamphear, B.J.; Martone, M.E.; Campbell, K.P.; Rhoads, R.E.; Knowlton, K.U. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 1999, 5, 320–326. [Google Scholar] [CrossRef] [Scilit]
- Kühl, U.; Lassner, D.; von Schlippenbach, J.; Poller, W.; Schultheiss, H.-P. Interferon-Beta Improves Survival in Enterovirus-Associated Cardiomyopathy. J. Am. Coll. Cardiol. 2012, 60, 1295–1296. [Google Scholar] [CrossRef] [Scilit]
- Pauschinger, M.; Bowles, N.E.; Fuentes-Garcia, F.J.; Pham, V.; Kühl, U.; Schwimmbeck, P.L.; Schultheiss, H.-P.; Towbin, J.A. Detection of Adenoviral Genome in the Myocardium of Adult Patients with Idiopathic Left Ventricular Dysfunction. Circulation 1999, 99, 1348–1354. [Google Scholar] [CrossRef] [Scilit]
- Kumar, K.; Guirgis, M.; Zieroth, S.; Lo, E.; Menkis, A.H.; Arora, R.C.; Freed, D.H. Influenza Myocarditis and Myositis: Case Presentation and Review of the Literature. Can. J. Cardiol. 2011, 27, 514–522. [Google Scholar] [CrossRef] [Scilit]
- Adler, Y.; Charron, P.; Imazio, M.; Badano, L.; Barón-Esquivias, G.; Bogaert, J.; Brucato, A.; Gueret, P.; Klingel, K.; Lionis, C.; et al. The 2015 ESC Guidelines on the diagnosis and management of pericardial diseases. Eur. Heart J. 2015, 36, 2873–2874. [Google Scholar] [CrossRef] [Scilit]
- Imazio, M.; Cecchi, E.; Demichelis, B.; Chinaglia, A.; Ierna, S.; Demarie, D.; Ghisio, A.; Pomari, F.; Belli, R.; Trinchero, R. Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008, 94, 498–501. [Google Scholar] [CrossRef] [Scilit]
- Imazio, M. Contemporary management of pericardial diseases. Curr. Opin. Cardiol. 2012, 27, 308–317. [Google Scholar] [CrossRef] [Scilit]
- Imazio, M.; Cecchi, E.; Demichelis, B.; Ierna, S.; Demarie, D.; Ghisio, A.; Pomari, F.; Coda, L.; Belli, R.; Trinchero, R. Indicators of Poor Prognosis of Acute Pericarditis. Circulation 2007, 115, 2739–2744. [Google Scholar] [CrossRef] [Scilit]
- Rey, F.; Delhumeau-Cartier, C.; Meyer, P.; Genne, D. Is acute idiopathic pericarditis associated with recent upper respiratory tract infection or gastroenteritis? A case-control study. BMJ Open 2015, 5, e009141. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Imazio, M.; Brucato, A.; Barbieri, A.; Ferroni, F.; Maestroni, S.; Ligabue, G.; Chinaglia, A.; Cumetti, D.; Casa, G.D.; Bonomi, F.; et al. Good Prognosis for Pericarditis with and Without Myocardial Involvement. Circulation 2013, 128, 42–49. [Google Scholar] [CrossRef] [Scilit]
- Imazio, M.; Trinchero, R. Myopericarditis: Etiology, management, and prognosis. Int. J. Cardiol. 2008, 127, 17–26. [Google Scholar] [CrossRef] [Scilit]
- Peretto, G.; Sala, S.; Rizzo, S.; Palmisano, A.; Esposito, A.; De Cobelli, F.; Campochiaro, C.; De Luca, G.; Foppoli, L.; Dagna, L.; et al. Ventricular Arrhythmias in Myocarditis. J. Am. Coll. Cardiol. 2020, 75, 1046–1057. [Google Scholar] [CrossRef] [Scilit]
- Ivey, K.S.; Edwards, K.M.; Talbot, H.K. Respiratory Syncytial Virus and Associations with Cardiovascular Disease in Adults. J. Am. Coll. Cardiol. 2018, 71, 1574–1583. [Google Scholar] [CrossRef] [Scilit]
- Madjid, M.; Connolly, A.T.; Nabutovsky, Y.; Safavi-Naeini, P.; Razavi, M.; Miller, C.C. Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators. Am. J. Cardiol. 2019, 124, 44–50. [Google Scholar] [CrossRef] [Scilit]
- Volling, C.; Hassan, K.; Mazzulli, T.; Green, K.; Al-Den, A.; Hunter, P.; Mangat, R.; Ng, J.; McGeer, A. Respiratory syncytial virus infection-associated hospitalization in adults: A retrospective cohort study. BMC Infect. Dis. 2014, 14, 665. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Adegbala, O.; Olagoke, O.; Akintoye, E.; Adejumo, A.C.; Oluwole, A.; Jara, C.; Williams, K.; Briasoulis, A.; Afonso, L. Predictors, Burden, and the Impact of Arrhythmia on Patients Admitted for Acute Myocarditis. Am. J. Cardiol. 2019, 123, 139–144. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Baksi, A.J.; Kanaganayagam, G.S.; Prasad, S.K. Arrhythmias in Viral Myocarditis and Pericarditis. Card. Electrophysiol. Clin. 2015, 7, 269–281. [Google Scholar] [CrossRef] [Scilit]
- Tse, G.; Yeo, J.M.; Chan, Y.W.; Lai, E.T.; Yan, B.P. What Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal Studies. Front. Physiol. 2016, 7, 308. [Google Scholar] [CrossRef] [Scilit]
- Cui, J.; Li, F.; Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019, 17, 181–192. [Google Scholar] [CrossRef] [Scilit]
- Yu, C. Cardiovascular complications of severe acute respiratory syndrome. Postgrad. Med. J. 2006, 82, 140–144. [Google Scholar] [CrossRef] [Scilit]
- Czubak, J.; Stolarczyk, K.; Orzeł, A.; Frączek, M.; Zatoński, T. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: A systematic literature review. Adv. Clin. Exp. Med. 2021, 30, 109–114. [Google Scholar] [CrossRef] [Scilit]
- Li, S.; Cheng, C.-W.; Fu, C.-L.; Chan, Y.-H.; Lee, M.-P.; Chan, J.; Yiu, S.-F. Left Ventricular Performance in Patients with Severe Acute Respiratory Syndrome. Circulation 2003, 108, 1798–1803. [Google Scholar] [CrossRef] [Scilit]
- Chong, P.Y.; Chui, P.; Ling, A.E.; Franks, T.J.; Tai, D.Y.; Leo, Y.S.; Kaw, G.J.; Wansaicheong, G.; Chan, K.P.; Ean Oon, L.L.; et al. Analysis of Deaths during the Severe Acute Respiratory Syndrome (SARS) Epidemic in Singapore: Challenges in Determining a SARS Diagnosis. Arch. Pathol. Lab. Med. 2004, 128, 95–204. [Google Scholar] [CrossRef] [Scilit]
- Alhogbani, T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann. Saudi Med. 2016, 36, 78–80. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Marshall, M. How COVID-19 can damage the brain. Nature 2020, 585, 342–343. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Delli Muti, N.; Finocchi, F.; Tossetta, G.; Salvio, G.; Cutini, M.; Marzioni, D.; Balercia, G. Could SARS-CoV-2 infection affect male fertility and sexuality? APMIS 2022, 130, 243–252. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tossetta, G.; Fantone, S.; Delli Muti, N.; Balercia, G.; Ciavattini, A.; Giannubilo, S.R.; Marzioni, D. Preeclampsia and severe acute respiratory syndrome coronavirus 2 infection: A systematic review. J. Hypertens. 2022, 40, 1629–1638. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Baigent, C.; Windecker, S.; Andreini, D.; Arbelo, E.; Barbato, E.; Bartorelli, A.L.; Baumbach, A.; Behr, E.R.; Berti, S.; Bueno, H.; et al. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: Part 1—Epidemiology, pathophysiology, and diagnosis. Eur. Heart J. 2022, 43, 1033–1058. [Google Scholar] [CrossRef] [Scilit]
- Pareek, M.; Singh, A.; Vadlamani, L.; Eder, M.; Pacor, J.; Park, J.; Ghazizadeh, Z.; Heard, A.; Cruz-Solbes, A.S.; Nikooie, R.; et al. Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients with Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). Am. J. Cardiol. 2021, 146, 99–106. [Google Scholar] [CrossRef] [Scilit]
- Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [Scilit]
- Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rola, P.; Doroszko, A.; Trocha, M.; Giniewicz, K.; Kujawa, K.; Gawryś, J.; Matys, T.; Gajecki, D.; Madziarski, M.; Zieliński, S.; et al. Usefulness of C2HEST Score in Predicting Clinical Outcomes of COVID-19 in Heart Failure and Non-Heart-Failure Cohorts. J. Clin. Med. 2022, 11, 3495. [Google Scholar] [CrossRef] [Scilit]
- Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020, 323, 1061–1069. [Google Scholar] [CrossRef] [Scilit]
- Lala, A.; Johnson, K.W.; Januzzi, J.L.; Russak, A.J.; Paranjpe, I.; Richter, F.; Zhao, S.; Somani, S.; Van Vleck, T.; Vaid, A.; et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection. J. Am. Coll. Cardiol. 2020, 76, 533–546. [Google Scholar] [CrossRef] [Scilit]
- Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020, 8, 420–422. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Inciardi, R.M.; Lupi, L.; Zaccone, G.; Italia, L.; Raffo, M.; Tomasoni, D.; Cani, D.S.; Cerini, M.; Farina, D.; Gavazzi, E.; et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020, 5, 819–824. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mohammad, S.; Aziz, R.; Al Mahri, S.; Malik, S.S.; Haji, E.; Khan, A.H.; Khatlani, T.S.; Bouchama, A. Obesity and COVID-19: What makes obese host so vulnerable? Immun. Ageing 2021, 18, 1. [Google Scholar] [CrossRef] [Scilit]
- Chang, W.-T.; Toh, H.S.; Liao, C.-T.; Yu, W.-L. Cardiac Involvement of COVID-19: A Comprehensive Review. Am. J. Med. Sci. 2021, 361, 14–22. [Google Scholar] [CrossRef] [Scilit]
- Guo, J.; Huang, Z.; Lin, L.; Lv, J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Am. Heart Assoc. 2020, 9, e016219. [Google Scholar] [CrossRef] [Scilit]
- Sokolski, M.; Reszka, K.; Suchocki, T.; Adamik, B.; Doroszko, A.; Drobnik, J.; Gorka-Dynysiewicz, J.; Jedrzejczyk, M.; Kaliszewski, K.; Kilis-Pstrusinska, K.; et al. History of Heart Failure in Patients Hospitalized Due to COVID-19: Relevant Factor of In-Hospital Complications and All-Cause Mortality up to Six Months. J. Clin. Med. 2022, 11, 241. [Google Scholar] [CrossRef] [Scilit]
- Bojkova, D.; Wagner, J.U.; Shumliakivska, M.; Aslan, G.S.; Saleem, U.; Hansen, A.; Luxán, G.; Günther, S.; Pham, M.D.; Krishnan, J.; et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc. Res. 2020, 116, 2207–2215. [Google Scholar] [CrossRef] [Scilit]
- Lindner, D.; Fitzek, A.; Bräuninger, H.; Aleshcheva, G.; Edler, C.; Meissner, K.; Scherschel, K.; Kirchhof, P.; Escher, F.; Schultheiss, H.-P.; et al. Association of Cardiac Infection with SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol. 2020, 5, 1281–1285. [Google Scholar] [CrossRef] [Scilit]
- Tavazzi, G.; Pellegrini, C.; Maurelli, M.; Belliato, M.; Sciutti, F.; Bottazzi, A.; Sepe, P.A.; Resasco, T.; Camporotondo, R.; Bruno, R.; et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur. J. Heart Fail. 2020, 22, 911–915. [Google Scholar] [CrossRef] [Scilit]
- Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020, 395, 1417–1418. [Google Scholar] [CrossRef] [Scilit]
- Fried, J.A.; Ramasubbu, K.; Bhatt, R.; Topkara, V.K.; Clerkin, K.J.; Horn, E.; Rabbani, L.R.; Brodie, D.; Jain, S.S.; Kirtane, A.J.; et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation 2020, 141, 1930–1936. [Google Scholar] [CrossRef] [Scilit]
- Puntmann, V.O.; Carerj, M.L.; Wieters, I.; Fahim, M.; Arendt, C.; Hoffmann, J.; Shchendrygina, A.; Escher, F.; Vasa-Nicotera, M.; Zeiher, A.M.; et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020, 5, 1265–1273. [Google Scholar] [CrossRef] [Scilit]
- Joy, G.; Artico, J.; Kurdi, H.; Lau, C.; Adam, R.D.; Menacho, K.M.; Pierce, I.; Captur, G.; Davies, R.; Schelbert, E.B.; et al. Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. JACC Cardiovasc. Imaging 2021, 14, 2155–2166. [Google Scholar] [CrossRef] [Scilit]
- Kotecha, T.; Knight, D.S.; Razvi, Y.; Kumar, K.; Vimalesvaran, K.; Thornton, G.; Patel, R.; Chacko, L.; Brown, J.T.; Coyle, C.; et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur. Heart J. 2021, 42, 1866–1878. [Google Scholar] [CrossRef] [Scilit]
- Vakili, K.; Fathi, M.; Pezeshgi, A.; Mohamadkhani, A.; Hajiesmaeili, M.; Rezaei-Tavirani, M.; Sayehmiri, F. Critical complications of COVID-19: A descriptive meta-analysis study. Rev. Cardiovasc. Med. 2020, 21, 433–442. [Google Scholar] [CrossRef] [Scilit]
- Shoar, S.; Hosseini, F.; Naderan, M.; Mehta, J.L. Meta-analysis of Cardiovascular Events and Related Biomarkers Comparing Survivors Versus Non-survivors in Patients with COVID-19. Am. J. Cardiol. 2020, 15, 50–61. [Google Scholar] [CrossRef] [Scilit]
- Modin, D.; Claggett, B.; Sindet-Pedersen, C.; Lassen, M.C.; Skaarup, K.G.; Jensen, J.U.; Fralick, M.; Schou, M.; Lamberts, M.; Gerds, T.; et al. Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. Circulation 2020, 142, 2080–2082. [Google Scholar] [CrossRef] [Scilit]
- Bangalore, S.; Sharma, A.; Slotwiner, A.; Yatskar, L.; Harari, R.; Shah, B.; Ibrahim, H.; Friedman, G.H.; Thompson, C.; Alviar, C.L.; et al. ST-Segment Elevation in Patients with Covid-19—A Case Series. N. Engl. J. Med. 2020, 382, 2478–2480. [Google Scholar] [CrossRef] [Scilit]
- Bridwell, R.; Long, B.; Gottlieb, M. Neurologic complications of COVID-19. Am. J. Emerg. Med. 2020, 38, 1549.e3–1549.e7. [Google Scholar] [CrossRef] [Scilit]
- Avila, J.; Long, B.; Holladay, D.; Gottlieb, M. Thrombotic complications of COVID-19. Am. J. Emerg. Med. 2021, 39, 213–218. [Google Scholar] [CrossRef] [Scilit]
- Giustino, G.; Pinney, S.P.; Lala, A.; Reddy, V.Y.; Johnston-Cox, H.A.; Mechanick, J.I.; Halperin, J.L.; Fuster, V. Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: JACC Focus Seminar. J. Am. Coll. Cardiol. 2020, 76, 2011–2023. [Google Scholar] [CrossRef] [Scilit]
- Wichmann, D. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann. Intern. Med. 2020, 173, 268–277. [Google Scholar] [CrossRef] [Scilit]
- Protasiewicz, M.; Reszka, K.; Kosowski, W.; Adamik, B.; Bombala, W.; Doroszko, A.; Gajecki, D.; Gawryś, J.; Guziński, M.; Jedrzejczyk, M.; et al. Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Score-Matched Cohort Study. J. Clin. Med. 2022, 11, 352. [Google Scholar] [CrossRef] [Scilit]
- Helms, J.; Tacquard, C.; Severac, F.; Leonard-Lorant, I.; Ohana, M.; Delabranche, X.; Merdji, H.; Clere-Jehl, R.; Schenck, M.; Fagot Gandet, F.; et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020, 46, 1089–1098. [Google Scholar] [CrossRef] [Scilit]
- Kochav, S.M.; Coromilas, E.; Nalbandian, A.; Ranard, L.S.; Gupta, A.; Chung, M.K.; Gopinathannair, R.; Biviano, A.B.; Garan, H.; Wan, E.Y. Cardiac Arrhythmias in COVID-19 Infection. Circ. Arrhythm. Electrophysiol. 2020, 13, e008719. [Google Scholar] [CrossRef] [Scilit]
- Bhatla, A.; Mayer, M.M.; Adusumalli, S.; Hyman, M.C.; Oh, E.; Tierney, A.; Moss, J.; Chahal, A.A.; Anesi, G.; Denduluri, S.; et al. COVID-19 and cardiac arrhythmias. Heart Rhythm 2020, 17, 1439–1444. [Google Scholar] [CrossRef] [Scilit]
- Angeli, F.; Spanevello, A.; De Ponti, R.; Visca, D.; Marazzato, J.; Palmiotto, G.; Feci, D.; Reboldi, G.; Fabbri, L.M.; Verdecchia, P. Electrocardiographic features of patients with COVID-19 pneumonia. Eur. J. Intern. Med. 2020, 78, 101–106. [Google Scholar] [CrossRef] [Scilit]
- Davis, H.E.; Assaf, G.S.; McCorkell, L.; Wei, H.; Low, R.J.; Re’em, Y.; Redfield, S.; Austin, J.P.; Akrami, A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine 2021, 38, 1010–1019. [Google Scholar] [CrossRef] [Scilit]
- Carfì, A.; Bernabei, R.; Landi, F. Persistent Symptoms in Patients After Acute COVID-19. JAMA 2020, 324, 603–605. [Google Scholar] [CrossRef] [Scilit]
- Raman, B.; Bluemke, D.A.; Lüscher, T.F.; Neubauer, S. Long COVID: Post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 2022, 43, 1157–1172. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Petersen, E.L.; Goßling, A.; Adam, G.; Aepfelbacher, M.; Behrendt, C.-A.; Cavus, E.; Cheng, B.; Fischer, N.; Gallinat, J.; Kühn, S.; et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. Eur. Heart J. 2022, 43, 1124–1137. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Alsaied, T.; Tremoulet, A.H.; Burns, J.C.; Saidi, A.; Dionne, A.; Lang, S.M.; Newburger, J.W.; de Ferranti, S.; Friedman, K.G. Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. Circulation 2021, 143, 78–88. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hoste, L.; Van Paemel, R.; Haerynck, F. Multisystem inflammatory syndrome in children related to COVID-19: A systematic review. Eur. J. Pediatr. 2021, 180, 2019–2034. [Google Scholar] [CrossRef] [Scilit]
- Kabeerdoss, J.; Pilania, R.K.; Karkhele, R.; Kumar, T.S.; Danda, D.; Singh, S. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: Immunological mechanisms, clinical manifestations and management. Rheumatol. Int. 2021, 41, 19–32. [Google Scholar] [CrossRef] [Scilit]
- Jiang, L.; Tang, K.; Levin, M.; Irfan, O.; Morris, S.K.; Wilson, K.; Klein, J.D.; Bhutta, Z.A. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect. Dis. 2020, 20, e276–e288. [Google Scholar] [CrossRef] [Scilit]
- Pouletty, M.; Borocco, C.; Ouldali, N.; Caseris, M.; Basmaci, R.; Lachaume, N.; Bensaid, P.; Pichard, S.; Kouider, H.; Morelle, G.; et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohort. Ann. Rheum. Dis. 2020, 79, 999–1006. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).


